NCT01612273|CompletedPhase 4DMC
Loading search results
Sponsor study identifier
interventional
92
1 country
1
Study Start
April 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2013
Actual (reported)Study Completion
June 2013
Actual (reported)To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2013
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2011
Date type not reportedThis date has not been verified as actual or estimated.
May 31, 2012
Actual (reported)June 5, 2012
Actual (reported)January 2013
Actual (reported)June 2013
Actual (reported)Primary Outcome - The amount of blood flow measured by finger doppler ultrasonography. The improvement of subjective symptom measured by questionaire.
Comparison of the PSV (peak systolic velocity) and EDV (end diastolic velocity) measured by finger doppler ultrasonography between disgren and aspirin groups after 6 weeks treatment.
6 weeks
Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
Division of Cardiology, Department of Internal Medicine, severance hospital
Seoul, Seoul, 120-752, South Korea
92 participants (actual enrollment reported by the registry).
First Submitted
May 31, 2012
First Posted
June 5, 2012
Study Start
April 2011
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
January 2013
Actual (reported)Study Completion
June 2013
Actual (reported)Last Updated
March 5, 2014
Record last verified: 2014-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: